KRAS and metastatic colorectal cancer: Another Phase Ib clinical trial of onvansertib combined with FOLFIRI and bevacizumab showed a manageable safety profile and a promising response rate compared with the historical response rate to FOLFIRI/bevacizumab in patients with KRAS-mutant metastatic colorectal cancer (mCRC) (Ahn et al., 2024).